Analysts Set Halozyme Therapeutics Inc. (HALO) PT at $16.13
Shares of Halozyme Therapeutics Inc. (NASDAQ:HALO) have earned an average recommendation of “Buy” from the eight research firms that are presently covering the stock. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $16.13.
Several analysts recently commented on the stock. Piper Jaffray Cos. raised their price target on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, September 16th. Wells Fargo & Co. restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, September 8th.
A number of hedge funds have recently bought and sold shares of the stock. Fisher Asset Management LLC raised its position in Halozyme Therapeutics by 2.4% in the second quarter. Fisher Asset Management LLC now owns 725,011 shares of the biopharmaceutical company’s stock worth $6,583,000 after buying an additional 17,231 shares in the last quarter. Panagora Asset Management Inc. raised its position in Halozyme Therapeutics by 15.5% in the first quarter. Panagora Asset Management Inc. now owns 742,510 shares of the biopharmaceutical company’s stock worth $7,032,000 after buying an additional 99,396 shares in the last quarter. Bellevue Group AG purchased a new position in Halozyme Therapeutics during the first quarter worth approximately $3,011,000. A.R.T. Advisors LLC raised its position in Halozyme Therapeutics by 12.4% in the first quarter. A.R.T. Advisors LLC now owns 120,238 shares of the biopharmaceutical company’s stock worth $1,138,000 after buying an additional 13,300 shares in the last quarter. Finally, Kennedy Capital Management Inc. raised its position in Halozyme Therapeutics by 4.0% in the first quarter. Kennedy Capital Management Inc. now owns 73,681 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 2,818 shares in the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.
Shares of Halozyme Therapeutics (NASDAQ:HALO) opened at 10.88 on Monday. The firm’s market capitalization is $1.39 billion. The company’s 50-day moving average is $11.23 and its 200-day moving average is $10.12. Halozyme Therapeutics has a 12-month low of $6.96 and a 12-month high of $18.65.
Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The business earned $33.30 million during the quarter, compared to analysts’ expectations of $29.94 million. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The firm’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same period last year, the company posted $0.02 earnings per share. On average, equities analysts forecast that Halozyme Therapeutics will post ($0.91) earnings per share for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.